Protecting the World from Pertussis and Other Emerging Diseases
BioNet is a leading developer and manufacturer of vaccines, specializing in recombinant and mRNA-based solutions targeting respiratory diseases and other global public health challenges. With a proven track record in research, development, and biomanufacturing, BioNet has successfully advanced proprietary recombinant pertussis vaccines from early-stage innovation to licensure.
New Pertussis Vaccine Set for Implementation
The Committee for Medicinal Products for Human Use (CHMP), a part of the European Medicines Agency (EMA), recently recommended approval of a pertussis vaccine for teenagers, adults and newborns.
According to the agency, VacPertagen could serve as an effective pertussis booster vaccine for kids aged 12 and above, helping prevent diagnoses of whooping cough. It could also offer passive protection to infants when administered to pregnant women in their 2nd or 3rd trimesters.
BioNet Receives Positive CHMP Opinion from EMA for VacPertagen, a Recombinant Vaccine against Pertussis
Lyon, November 18, 2025: BioNet, a biotechnology company focused on next-generation vaccines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorisation in the European Union for VacPertagen, a standalone acellular pertussis vaccine.
CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product VacPertagen, a vaccine intended for prophylaxis against pertussis.
